Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...336337338339340341342343344345346...10671068»
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  3D-Printed Polypyrrole Microneedle Arrays for Electronically Controlled Transdural Drug Release. (Pubmed Central) -  Apr 13, 2022   
    PPy microneedles demonstrated an electronically controlled release of steroid dexamethasone (Dexa) in a novel in vitro transdural model and in vivo...Following electrically activated Dexa release, inflammation was reduced, as demonstrated by a decrease in nitric oxide and proinflammatory cytokines Il-6 and MCP-1. These results demonstrate the feasibility of PPy-coated microneedles for the transdural delivery of anti-inflammatory drugs to the central nervous system.
  • ||||||||||  fluticasone / Generic mfg.
    Observational data, Journal, HEOR, Real-world evidence:  Fluticasone-Based versus Budesonide-Based Triple Therapies in COPD: Real-World Comparative Effectiveness and Safety. (Pubmed Central) -  Apr 13, 2022   
    In a real-world clinical setting of COPD treatment, budesonide-based triple therapy given in two inhalers was generally as effective at reducing exacerbations as fluticasone-based triple therapy. However, the budesonide-based triple therapy was associated with a lower incidence of severe pneumonia and possibly also of all-cause death, especially among patients with no prior exacerbations for whom triple therapy is not recommended.
  • ||||||||||  remdesivir / Generic mfg., dexamethasone / Generic mfg.
    Journal:  A Simple Prognostic Score for Critical COVID-19 Derived from Patients without Comorbidities Performs Well in Unselected Patients. (Pubmed Central) -  Apr 13, 2022   
    This score performed well in an unselected patient cohort (n = 1228, 100% unvaccinated) predominantly infected by the alpha variant (AUC: 0.718, 95% CI: 0.683-0.753), as well as in a mixed cohort (n = 527, 65% unvaccinated) predominantly infected by the delta variant (AUC: 0.708, 95% CI: 0.656-0.760). Therefore, we propose that a combination of standard biomarkers of acute inflammatory response, cell death and hypercoagulability reflects the severity of COVID-19 per se independently of comorbidities, age and sex, being of value for risk stratification in unselected patients.
  • ||||||||||  dexamethasone / Generic mfg., cefotaxime / Generic mfg.
    FORTY YEARS OF ADULT PNEUMOCOCCAL MENINGITIS. BARCELONA 1979-2018 (Station 01) -  Apr 13, 2022 - Abstract #ISPPD2022ISPPD_192;    
    These reductions were linked to the introduction of pneumococcal conjugate vaccines, along with the adjuvant use of dexamethasone. Pneumococcal meningitis focus determines serotype and mortality.
  • ||||||||||  carfilzomib / Generic mfg.
    Trial completion, Enrollment change:  A Phase II Study of Carfilzomib in Relapsed Waldenstr (clinicaltrials.gov) -  Apr 13, 2022   
    P2,  N=7, Completed, 
    Trial completion date: Aug 2022 --> May 2022 Active, not recruiting --> Completed | N=55 --> 7
  • ||||||||||  dexamethasone / Generic mfg., epinephrine / Generic mfg.
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  DBBA: Duration of Blockade of Peripheral Nerves With Bupivacaine Depending of the Adjuvants (clinicaltrials.gov) -  Apr 13, 2022   
    P=N/A,  N=68, Completed, 
    Recruiting --> Completed Recruiting --> Completed | N=100 --> 68 | Trial completion date: Jan 2025 --> Apr 2022 | Trial primary completion date: Jan 2025 --> Apr 2022
  • ||||||||||  dexamethasone / Generic mfg., dexamethasone injection / Generic mfg.
    Trial completion, Phase classification:  ROIDS-Dose: Randomized Open Investigation Determining Steroid Dose (clinicaltrials.gov) -  Apr 12, 2022   
    P3,  N=142, Completed, 
    N=76 --> 12 | Recruiting --> Suspended Recruiting --> Completed | Phase classification: P4 --> P3
  • ||||||||||  dexamethasone / Generic mfg.
    Clinical, Journal:  Systemic Steroid at Discharge After Hospitalization for Pediatric Asthma: A prospective pilot study. (Pubmed Central) -  Apr 12, 2022   
    A total of 56 patients were included in the study, 29 (52%) received dexamethasone inpatient and then were discharged without additional prescribed systemic corticosteroids...In multivariable models, being discharged without systemic corticosteroid prescription was associated with poorer asthma control after discharge [beta (95% CI), -2.21 (-2.65 to -1.77)] and more missed school days [coefficient estimate (95% CI), 0.87 (0.07 to 1.68)]. After hospitalization for an asthma exacerbation, patients not given systemic corticosteroids at discharge tended to have worse asthma control following discharge despite having less severe disease and requiring less aggressive inpatient management.
  • ||||||||||  dexamethasone / Generic mfg.
    Preclinical, Journal:  MMP9 mRNA is a potential diagnostic and treatment monitoring marker for PTSD: Evidence from mice and humans. (Pubmed Central) -  Apr 12, 2022   
    In contrast, blood TNFR1 and IL1R2 were markedly underexpressed in PTSD patients. In conclusion, we found translational evidence supporting that, I, TNFR1 and MMP9 mRNA expression might be involved in PTSD pathobiology, II, might constitute potential diagnostic blood biomarkers for PTSD and, importantly, III, post-dexamethasone blood MMP9 hyperexpression, which speculatively results from post-dexamethasone underexpression of IL1R2, might serve also as potential treatment monitoring biomarker for PTSD.
  • ||||||||||  Preclinical, Journal:  Ex vivo drug sensitivity screening in multiple myeloma identifies drug combinations that act synergistically. (Pubmed Central) -  Apr 12, 2022   
    In agreement with clinical studies, clinically approved combinations, such as triple combination of selinexor plus bortezomib plus dexamethasone, acted synergistically, and synergies required low drug concentrations (0.1 nM bortezomib, 10 nM selinexor and 4 nM dexamethasone). In summary, our drug screening provided results within a clinically actionable 5-day time frame and identified synergistic drug efficacies in patient-derived MM cells that may aid future therapy choices.
  • ||||||||||  Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
    Trial completion:  KPT-330+RICE: KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma (clinicaltrials.gov) -  Apr 12, 2022   
    P1,  N=22, Completed, 
    Further research will be conducive to establishing a better treatment scheme for such child patients. Active, not recruiting --> Completed
  • ||||||||||  dexamethasone / Generic mfg.
    Journal, Monotherapy:  Liver injury in patients with moderate II COVID-19 who received dexamethasone monotherapy (Pubmed Central) -  Apr 12, 2022   
    Liver injury worsened in 41% of patients after Dex monotherapy, but there was no significant difference in the frequency before Dex monotherapy between the liver injury group and the nonliver injury group, and the degree of liver injury was mild in all cases, improving in 38% of the liver injury group. Dex monotherapy was a safe treatment for moderate II COVID-19, which frequently resulted in liver injury.
  • ||||||||||  dexamethasone / Generic mfg., atorvastatin / Generic mfg., tranexamic acid oral / Generic mfg.
    Retrospective data, Review:  Effectiveness Comparisons of Drug Therapy on Chronic Subdural Hematoma Recurrence: A Bayesian Network Meta-Analysis and Systematic Review. (Pubmed Central) -  Apr 12, 2022   
    Four drug interventions [ATO+DXM (OR = 0.06, 95% CrI 0.01, 0.89), DXM (OR = 0.18, 95% CrI 0.07, 0.41), tranexamic acid (TXA) (OR = 0.26, 95% CrI 0.07, 0.41), and ATO (OR = 0.41, 95% CrI 0.12, 0.90)] achieved statistical significance in improving recurrence in CSDH patients compared with the placebo (PLB) or standard neurosurgical treatment (SNT) group...Multicenter rigorous designed prospective randomized trials are still needed to evaluate the role of various drug interventions in improving neurological function or outcome. Systematic Review Registration: (https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=299491), identifier (CRD 42022299491).
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Keratoconjunctivitis as a Single Entity in X-linked Agammaglobulinemia? (Pubmed Central) -  Apr 12, 2022   
    Whereas steroid eye drops like dexamethasone could control the symptoms and the corneal scarring progression as short time therapy options, ciclosporin A eye drops showed problems in therapy adherence in long-time use...Antineovascular subconjunctival application did not show any relevant effect in one-time use. Artificial tears were needed as basic therapy.
  • ||||||||||  Sarclisa (isatuximab-irfc) / Sanofi
    Trial completion date, Trial primary completion date:  SKylaRk: KRDI in Transplant-Eligible MM (clinicaltrials.gov) -  Apr 12, 2022   
    P2,  N=50, Recruiting, 
    Artificial tears were needed as basic therapy. Trial completion date: Sep 2021 --> Mar 2025 | Trial primary completion date: Sep 2021 --> Jul 2022
  • ||||||||||  dexamethasone / Generic mfg.
    Trial completion date, Trial primary completion date:  CORE: Bioequivalence Study of Prednisolone and Dexamethasone (clinicaltrials.gov) -  Apr 12, 2022   
    P1,  N=24, Recruiting, 
    Trial completion date: Sep 2021 --> Mar 2025 | Trial primary completion date: Sep 2021 --> Jul 2022 Trial completion date: Oct 2021 --> May 2022 | Trial primary completion date: Oct 2021 --> May 2022
  • ||||||||||  dexamethasone / Generic mfg.
    Enrollment open, Trial initiation date:  Dexhia: Efficacy of Soluble Dexamethasone in Refractory Sciatica (clinicaltrials.gov) -  Apr 12, 2022   
    P3,  N=106, Recruiting, 
    Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Sep 2021 --> Dec 2021